Under construction – not a live service
Sign in
Taking peopleNo phase

Management of Children With Persistent ITP, A Novel Approach

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 10 years old?

Source: NCT07068126, who can take part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Assiut University
Trial code
NCT07068126
Record updated
16 July 2025
Original description
The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer are:Read full original descriptionShow less

"The Safety and Efficacy of Mini-Pool IVIG Initiation and Maintenance Therapy for Management of Children With Persistent ITP, A Novel Approach for LMICs"

The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer are:

Can mini-pool IVIG raise platelet levels in children with persistent ITP?

Can it reduce bleeding episodes and hospital visits?

What side effects, if any, are seen with this treatment?

There is no comparison group in this study. All participants will receive mini-pool IVIG, which is made from small pools of donated plasma using a cost-effective process.

Participants will:

Receive one dose of mini-pool IVIG through a vein over 6 to 8 hours

Receive follow-up doses every 2 to 4 weeks for up to 5 doses, based on their platelet count

Have regular blood tests and checkups during the study and for 6 months after treatment

Report on bleeding episodes, physical activity, school attendance, and side effects

Inclusion: Gender: Males and Females; Persistent ITP according to ASH definition; No history of treatment with thrombopoietin agonists.

Exclusion: Previous history of ICH; Difficult venous access; Congenital thrombocytopenia, secondary ITP and non-immune thrombocytopenia.

ClinicalTrials.gov NCT07068126